<DOC>
	<DOCNO>NCT00022646</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving one drug give drug different way may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness three different regimen pemetrexed disodium plus gemcitabine treating patient locally advanced metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Pemetrexed Disodium Plus Gemcitabine Treating Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare tumor response rate patient locally advanced metastatic non-small cell lung cancer treat 3 different schedule pemetrexed disodium gemcitabine . - Compare duration response , time progressive disease , time treatment failure , survival time patient treat regimen . - Compare quantitative qualitative toxic effect regimens patient . OUTLINE : This randomize , open-label study . Patients stratify accord stage disease ( IIIB v IV ) ECOG performance status ( 0 vs 1 ) . Patients randomize one three treatment arm . - Arm I : Patients receive pemetrexed disodium IV 10 minute day 1 follow gemcitabine IV 30 minute day 1 8 . - Arm II : Patients receive gemcitabine IV 30 minute day 1 8 follow pemetrexed disodium IV 10 minute day 1 . - Arm III : Patients receive gemcitabine IV 30 minute day 1 pemetrexed disodium IV 10 minute follow gemcitabine IV 30 minute day 8 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . Patients stable respond disease may receive 6 additional course therapy . Patients follow every 2 month 1 year every 6 month 4 year . PROJECTED ACCRUAL : A total 180 patient ( 60 per treatment arm ) accrue study within 20 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advanced metastatic nonsmall cell lung cancer Stage IIIB disease ineligible combine modality therapy OR Stage IV disease Measurable disease No clinically detectable ( physical exam ) thirdspace fluid collection ( e.g. , ascites pleural effusion ) control drainage procedure No brain metastasis ( even treat ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( 5 time ULN liver metastasis present ) Alkaline phosphatase great 3 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine clearance least 45 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able take folic acid cyanocobalamin ( vitamin B12 ) supplementation No uncontrolled infection No concurrent chronic debilitate disease No weight loss 10 % within past 6 week No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer noninvasive carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic genetic therapy lung cancer No concurrent immunomodulating agent Chemotherapy : No prior chemotherapy lung cancer Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy different site recover No prior radiotherapy 25 % bone marrow No prior radiotherapy whole pelvis No prior radiotherapy primary disease No concurrent radiotherapy Surgery : More 4 week since prior major surgery Other : No aspirin nonsteroidal antiinflammatory agent 2 day , , 2 day pemetrexed disodium administration ( 5 day longacting agent piroxicam , naproxen , diflunisal , nabumetone ) No concurrent cytostatic cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>